Also known as Enablex
Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis; however in 2010 US rights for were sold to Warner Chilcott for 400 million US$.Source: Wikipedia
Estimated Total Cost: $124.53 for an average of 28 days supply
Patients are most commonly prescribed darifenacin to treat involuntary urination, frequent urination, urge incontinence, and benign prostatic hyperplasia (bph).